Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Other Working Capital Changes (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Other Working Capital Changes for 17 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 560.29% to $6.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, up 19.63% year-over-year, with the annual reading at $3.4 million for FY2025, 19.63% up from the prior year.
  • Other Working Capital Changes hit $6.7 million in Q4 2025 for Integra Lifesciences Holdings, up from -$5.7 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $13.8 million in Q4 2022 to a low of -$22.1 million in Q4 2023.
  • Historically, Other Working Capital Changes has averaged $111550.0 across 5 years, with a median of $1.6 million in 2024.
  • Biggest five-year swings in Other Working Capital Changes: skyrocketed 6179.52% in 2022 and later tumbled 1536.6% in 2025.
  • Year by year, Other Working Capital Changes stood at -$19.6 million in 2021, then surged by 170.76% to $13.8 million in 2022, then plummeted by 259.65% to -$22.1 million in 2023, then surged by 104.61% to $1.0 million in 2024, then soared by 560.29% to $6.7 million in 2025.
  • Business Quant data shows Other Working Capital Changes for IART at $6.7 million in Q4 2025, -$5.7 million in Q3 2025, and $2.1 million in Q2 2025.